CL2004000797A1 - Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc - Google Patents

Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc

Info

Publication number
CL2004000797A1
CL2004000797A1 CL200400797A CL2004000797A CL2004000797A1 CL 2004000797 A1 CL2004000797 A1 CL 2004000797A1 CL 200400797 A CL200400797 A CL 200400797A CL 2004000797 A CL2004000797 A CL 2004000797A CL 2004000797 A1 CL2004000797 A1 CL 2004000797A1
Authority
CL
Chile
Prior art keywords
colorrectal
quinazolina
quinasa
panc
aurora
Prior art date
Application number
CL200400797A
Other languages
English (en)
Inventor
Nicola Murdoch Mortlock Heron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2004000797A1 publication Critical patent/CL2004000797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CL200400797A 2003-04-16 2004-04-14 Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc CL2004000797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16

Publications (1)

Publication Number Publication Date
CL2004000797A1 true CL2004000797A1 (es) 2005-05-27

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400797A CL2004000797A1 (es) 2003-04-16 2004-04-14 Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc

Country Status (23)

Country Link
US (1) US7691867B2 (es)
EP (1) EP1613619B1 (es)
JP (1) JP4709139B2 (es)
KR (1) KR20060003351A (es)
CN (1) CN1809557B (es)
AR (1) AR043875A1 (es)
AT (1) ATE390422T1 (es)
AU (1) AU2004232527A1 (es)
BR (1) BRPI0409427A (es)
CA (1) CA2522079A1 (es)
CL (1) CL2004000797A1 (es)
CO (1) CO5640037A2 (es)
DE (1) DE602004012725T2 (es)
ES (1) ES2301981T3 (es)
HK (1) HK1086573A1 (es)
IS (1) IS8125A (es)
MX (1) MXPA05011076A (es)
NO (1) NO20054842L (es)
RU (1) RU2005135337A (es)
TW (1) TW200510392A (es)
UY (1) UY28271A1 (es)
WO (1) WO2004094410A1 (es)
ZA (1) ZA200508372B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
WO2006040522A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP1819698B1 (en) 2004-11-17 2011-02-23 Rexahn Pharmaceuticals, Inc. 1-[(6-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
WO2006129064A1 (en) * 2005-05-28 2006-12-07 Astrazeneca Ab Quinazolines and their use as aurora kinase inhibitors
US20080269500A1 (en) * 2005-09-22 2008-10-30 Astrazeneca Ab Process for the Preparation of 4-Aminopyrazole Derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090233950A1 (en) * 2006-03-02 2009-09-17 Frederic Henri Jung Quinazoline derivatives
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN103012428A (zh) 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
JP6567505B2 (ja) * 2013-09-19 2019-08-28 ピエール、ファーブル、メディカマン キナゾリン誘導体およびｄｎａメチルトランスフェラーゼ阻害剤としてのその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
DE69622183D1 (de) * 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
JP4870304B2 (ja) * 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
PL360439A1 (en) * 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7560558B2 (en) * 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
AU2003290322A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Quinazoline compounds
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AR043875A1 (es) 2005-08-17
MXPA05011076A (es) 2006-01-24
ATE390422T1 (de) 2008-04-15
JP4709139B2 (ja) 2011-06-22
RU2005135337A (ru) 2006-06-10
DE602004012725T2 (de) 2009-04-16
TW200510392A (en) 2005-03-16
CN1809557A (zh) 2006-07-26
BRPI0409427A (pt) 2006-04-18
DE602004012725D1 (de) 2008-05-08
CO5640037A2 (es) 2006-05-31
JP2006523660A (ja) 2006-10-19
EP1613619B1 (en) 2008-03-26
US7691867B2 (en) 2010-04-06
AU2004232527A1 (en) 2004-11-04
EP1613619A1 (en) 2006-01-11
KR20060003351A (ko) 2006-01-10
WO2004094410A1 (en) 2004-11-04
NO20054842L (no) 2005-11-08
ES2301981T3 (es) 2008-07-01
IS8125A (is) 2005-11-11
UY28271A1 (es) 2004-11-30
US20060270692A1 (en) 2006-11-30
ZA200508372B (en) 2007-04-25
HK1086573A1 (en) 2006-09-22
CN1809557B (zh) 2012-07-04
CA2522079A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CL2004000797A1 (es) Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
PL1830876T3 (pl) Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
HK1102544A1 (en) Use of herbal compositions in the manufacture of medicine for treating prostate cancer
CL2004000985A1 (es) Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
ZA200610132B (en) Therapy of platinum-resistant cancer
BRPI0717907A2 (pt) "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
GEP20125469B (en) Inhibitors of akt activity
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
IL202505A (en) 2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
WO2006050155A3 (en) Cancer therapeutic compositions
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
BRPI0813928A2 (pt) Polialilamina reticulada, composição farmacêutica, agente terapêutico ou profilático para hiperfosfatemia, método terapêutico ou profilático para hiperfosfatemia, uso da polialilamina reticulada, e, composto para terapia ou profilaxia de hiperfosfatemia
IL180256A0 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
BR112012006062A2 (pt) novos compostos e respectivo uso terapêutico para inibição de proteína quinase
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
BRPI0717477A2 (pt) Agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso de um inibidor de her2 e um agente terapêutico hormonal ou agente anticâncer
IL175689A0 (en) Enoxaparin for the treatment of cancer
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen